{"id":61835,"date":"2025-09-09T10:06:54","date_gmt":"2025-09-09T08:06:54","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/revoab-a-new-service-for-antibody-developability-engineering\/"},"modified":"2025-09-09T10:06:54","modified_gmt":"2025-09-09T08:06:54","slug":"revoab-a-new-service-for-antibody-developability-engineering","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/revoab-a-new-service-for-antibody-developability-engineering\/","title":{"rendered":"‘RevoAb\u2122’, A New Service for Antibody Developability Engineering"},"content":{"rendered":"
\n

SENDAI, Japan–(BUSINESS WIRE)–RevolKa Ltd. (RevolKa), a venture-backed biotech company providing a cutting-edge AI-driven protein engineering technology platform, called ai<\/i>Protein\u00ae<\/sup> is pleased to announce the launch of a new contract research service, ‘RevoAb\u2122’. This service engineers antibodies to improve physicochemical properties while protecting antigen binding affinity.<\/p>\n

<\/a>
<\/a><\/p>\n

\nAbout RevoAb\u2122
\n
<\/b>Since December 2023, RevolKa has offered contract research services for antibody engineering using ai<\/i>Protein\u00ae<\/sup>, its AI-driven protein engineering technology, through FUJIFILM Wako Pure Chemical Corporation in Japan.
\n
RevoAb\u2122 is a new online service for antibody developability engineering based on “RevolKa’s Refined Naturalness Design concept,” This refines antibody framework sequences to be close to those in naturally occurring antibodies. The pilot version was released in Japan in July 2025. Based on customer feedback, we are now launching an upgraded RevoAb\u2122 world-wide.
\n
With RevoAb\u2122, users can instantly access multiple antibody sequences with potential improvement in properties, such as expression levels, stability, solubility, etc., at low prices.
\n
For more details, please visit.:
\n
https:\/\/revoab.revolka.com\/en\/<\/a><\/p>\n

\nStory behind RevoAb\u2122 Development.
\n
<\/b>Antibodies are proteins that provide immune protection by recognizing and binding to substances (antigens) from infecting bacteria and viruses. They are widely used in industries, such as therapeutics and diagnostics. However, antibodies are often fragile for industrial applications, and enhancing their properties typically requires significant time and resources.<\/p>\n

\nRevolKa has successfully engineered many proteins using ai<\/i>Protein\u00ae<\/sup> in collaboration with customers. For antibodies, we identified that part of ai<\/i>Protein\u00ae<\/sup> could become a valuable tool for scientists struggling with suboptimal physicochemical properties. It is engineering of framework sequences of antibody by using RevolKa’s Refined Naturalness Design concept. We developed RevoAb\u2122 to provide research scientists with \u201cWinning Antibody Sequences\u201d instantly online.<\/p>\n

\nFees<\/b><\/p>\n\n\n\n\n\n
Target<\/td>\n\n

\nOrigins<\/p>\n<\/td>\n

\n

\nPrice per target<\/p>\n<\/td>\n

\n

\nRemarks<\/p>\n<\/td>\n<\/tr>\n

\n

\nFragment of variable regions(Fv)<\/p>\n<\/td>\n

\n

\nHuman<\/p>\n

\nRabbit<\/p>\n

\nMouse<\/p>\n

\nRat<\/p>\n<\/td>\n

\n

\nUSD700<\/p>\n<\/td>\n

\n

\nOne target: one heavy chain sequence + one light chain sequence.<\/p>\n

\n\u00a0<\/p>\n

\nHumanized Fv considered as human.<\/p>\n<\/td>\n<\/tr>\n

\n

\nOthers<\/p>\n<\/td>\n

\n

\nUSD350<\/p>\n<\/td>\n<\/tr>\n

\n

\nVariable heavy domain of heavy chain(VHH)<\/p>\n<\/td>\n

\n

\nCamelids<\/p>\n<\/td>\n

\n

\nUSD350<\/p>\n<\/td>\n

\n

\nHumanized VHH not supported.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nRegistration
\n
<\/b>Please review and agree to the terms of use and privacy policy before filling out the form on the landing page.<\/p>\n

Contacts<\/b> <\/p>\n

\nInquiries Regarding RevoAb\u2122<\/b>
For any question, please contact us at support-revotune@revolka.co.jp<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SENDAI, Japan–(BUSINESS WIRE)–RevolKa Ltd. (RevolKa), a venture-backed biotech company providing a cutting-edge AI-driven protein engineering technology platform, called aiProtein\u00ae is pleased to announce the launch of a new contract research service, ‘RevoAb\u2122’. This service engineers antibodies to improve physicochemical properties while protecting antigen binding affinity. About RevoAb\u2122 Since December 2023, RevolKa has offered contract research … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61835","6":"format-standard","7":"category-industry"},"yoast_head":"\n'RevoAb\u2122', A New Service for Antibody Developability Engineering - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/revoab-a-new-service-for-antibody-developability-engineering\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"'RevoAb\u2122', A New Service for Antibody Developability Engineering - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SENDAI, Japan–(BUSINESS WIRE)–RevolKa Ltd. (RevolKa), a venture-backed biotech company providing a cutting-edge AI-driven protein engineering technology platform, called aiProtein\u00ae is pleased to announce the launch of a new contract research service, ‘RevoAb\u2122’. This service engineers antibodies to improve physicochemical properties while protecting antigen binding affinity. About RevoAb\u2122 Since December 2023, RevolKa has offered contract research ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/revoab-a-new-service-for-antibody-developability-engineering\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-09T08:06:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250902207491\/en\/2568756\/22\/logo_org.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revoab-a-new-service-for-antibody-developability-engineering\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revoab-a-new-service-for-antibody-developability-engineering\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"‘RevoAb\u2122’, A New Service for Antibody Developability Engineering\",\"datePublished\":\"2025-09-09T08:06:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revoab-a-new-service-for-antibody-developability-engineering\\\/\"},\"wordCount\":367,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revoab-a-new-service-for-antibody-developability-engineering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250902207491\\\/en\\\/2568756\\\/22\\\/logo_org.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revoab-a-new-service-for-antibody-developability-engineering\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revoab-a-new-service-for-antibody-developability-engineering\\\/\",\"name\":\"'RevoAb\u2122', A New Service for Antibody Developability Engineering - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revoab-a-new-service-for-antibody-developability-engineering\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revoab-a-new-service-for-antibody-developability-engineering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250902207491\\\/en\\\/2568756\\\/22\\\/logo_org.jpg\",\"datePublished\":\"2025-09-09T08:06:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revoab-a-new-service-for-antibody-developability-engineering\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revoab-a-new-service-for-antibody-developability-engineering\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revoab-a-new-service-for-antibody-developability-engineering\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250902207491\\\/en\\\/2568756\\\/22\\\/logo_org.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250902207491\\\/en\\\/2568756\\\/22\\\/logo_org.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/revoab-a-new-service-for-antibody-developability-engineering\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"‘RevoAb\u2122’, A New Service for Antibody Developability Engineering\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"'RevoAb\u2122', A New Service for Antibody Developability Engineering - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/revoab-a-new-service-for-antibody-developability-engineering\/","og_locale":"en_US","og_type":"article","og_title":"'RevoAb\u2122', A New Service for Antibody Developability Engineering - Pharma Trend","og_description":"SENDAI, Japan–(BUSINESS WIRE)–RevolKa Ltd. (RevolKa), a venture-backed biotech company providing a cutting-edge AI-driven protein engineering technology platform, called aiProtein\u00ae is pleased to announce the launch of a new contract research service, ‘RevoAb\u2122’. This service engineers antibodies to improve physicochemical properties while protecting antigen binding affinity. About RevoAb\u2122 Since December 2023, RevolKa has offered contract research ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/revoab-a-new-service-for-antibody-developability-engineering\/","og_site_name":"Pharma Trend","article_published_time":"2025-09-09T08:06:54+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250902207491\/en\/2568756\/22\/logo_org.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/revoab-a-new-service-for-antibody-developability-engineering\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/revoab-a-new-service-for-antibody-developability-engineering\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"‘RevoAb\u2122’, A New Service for Antibody Developability Engineering","datePublished":"2025-09-09T08:06:54+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/revoab-a-new-service-for-antibody-developability-engineering\/"},"wordCount":367,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/revoab-a-new-service-for-antibody-developability-engineering\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250902207491\/en\/2568756\/22\/logo_org.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/revoab-a-new-service-for-antibody-developability-engineering\/","url":"https:\/\/pharma-trend.com\/en\/revoab-a-new-service-for-antibody-developability-engineering\/","name":"'RevoAb\u2122', A New Service for Antibody Developability Engineering - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/revoab-a-new-service-for-antibody-developability-engineering\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/revoab-a-new-service-for-antibody-developability-engineering\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250902207491\/en\/2568756\/22\/logo_org.jpg","datePublished":"2025-09-09T08:06:54+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/revoab-a-new-service-for-antibody-developability-engineering\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/revoab-a-new-service-for-antibody-developability-engineering\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/revoab-a-new-service-for-antibody-developability-engineering\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250902207491\/en\/2568756\/22\/logo_org.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250902207491\/en\/2568756\/22\/logo_org.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/revoab-a-new-service-for-antibody-developability-engineering\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"‘RevoAb\u2122’, A New Service for Antibody Developability Engineering"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61835","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61835"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61835\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61835"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61835"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61835"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}